Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > WXXWY WUXI BIOLGCS ADR > Key Indicators
WXXWY WUXI BIOLGCS ADR
13.650
+0.690+5.32%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(FY)2021/12/31(Q4)2021/12/31(Q2)2021/06/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
69.03% 174.5202 -6.79% 147.1602 -6.79% 147.1602 244.28% 103.2497
Receivable Turnover(T)
-11.56% 3.1672 23.23% 3.7717 23.23% 3.7717 5.01% 3.5814
Inventory Turnover(T)
6.68% 3.7109 -5.07% 3.9408 -5.07% 3.9408 -36.41% 3.4785
Fixed Assets Turnover(T)
13.74% 0.6614 10.52% 0.6308 10.52% 0.6308 -5.31% 0.5815
Total Asset Rate(T)
14.48% 0.2875 16.96% 0.2819 16.96% 0.2819 -10.10% 0.2511
ROIC
5.40% 10.566% 30.92% 11.155% 30.92% 11.155% 2.68% 10.025%
ROE
1.09% 12.060% 26.62% 12.825% 26.62% 12.825% 1.76% 11.930%
ROA
3.13% 8.965% 27.99% 9.284% 27.99% 9.284% 3.43% 8.693%
Efficiency Ratios
ROE 5 Year Average
-- -- -49.98% 10.994% -- -- -- --
ROA 5 Year Average
-- -- 2.13% 8.060% -- -- -- --
Average 5 Years ROIC
-- -- -9.36% 9.387% -- -- -- --
Profitability Ratios TTM
Gross Margin
-9.27% 45.419% 3.98% 46.928% 3.98% 46.928% 21.85% 50.062%
Operating Margin
-15.54% 32.486% 7.28% 33.670% 7.28% 33.670% 48.33% 38.464%
Net Margin
-9.91% 31.180% 9.43% 32.930% 9.43% 32.930% 15.05% 34.612%
EBITDA Margin
-9.93% 0.3748% 6.51% 0.4387% 6.51% 0.4387% 32.48% 0.4161%
R & D Expense Ratio
37.53% 5.020% -9.98% 4.870% -9.98% 4.870% -42.61% 3.650%
Sales Expense Ratio
-24.24% 1.000% -27.98% 1.210% -27.98% 1.210% -42.61% 1.320%
Administration Expense Rate
-1.35% 8.010% -6.59% 8.510% -6.59% 8.510% -16.63% 8.120%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-43.85% 5.586% -47.34% 6.412% -47.34% 6.412% -52.45% 9.950%
Total Assets to Common Equity
5.01% 137.757% -3.14% 136.414% -3.14% 136.414% -13.69% 131.185%
Debt to Asset Ratio
-7.81% 12.764% -17.87% 13.307% -17.87% 13.307% -48.72% 13.845%
Current Ratio
-43.15% 2.2962 -25.09% 2.3656 -25.09% 2.3656 36.24% 4.0392
Quick Ratio
-43.49% 1.823 -26.15% 1.8473 -26.15% 1.8473 38.20% 3.2258
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- 15.93% 59.531% -- -- -- --
Revenue CAGR(5Y)
-- -- 1.74% 59.750% -- -- -- --
Net Income CAGR(3Y)
-- -- -14.97% 75.154% -- -- -- --
Net Income CAGR(5Y)
-- -- -16.92% 88.842% -- -- -- --
Currency Unit
CNYCNYCNYCNY

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug substance cGMP manufacture; commercial drug substance cGMP manufacture; drug product cGMP fill and finish; antibody drug conjugates; regulatory affairs; and technologies and platforms. The company was founded on May 24, 2010 and is headquartered in Wuxi, China.
CEO: Dr. Chen Zhisheng
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist